Comparisons of aggregate health expenditure across different countries have become popular over the last three decades as they permit a systematic investigation of the impact of different institutional regimes and other explanatory variables. Over the years, several regression analyses based on...

This paper investigates the economic burden of multiple sclerosis (MS) in Sweden in 1994. The cost structure was compared with costs from a similar study from 1991 and 3 studies from the UK. The cost-of-illness method, based on the human capital theory, was used to estimate the economic burden...

Background: ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) showed in hypertensive patients that blood pressure-lowering treatment with an amlodipine-based regimen reduces events compared with an atenolol-based regimen and that atorvastatin was more effective than placebo. Abstract: Objective:...

Background: The Fracture Intervention Trial (FIT) demonstrated that the bisphosphonate alendronate reduces the risk of hip, spine and wrist fracture in osteoporotic women by approximately one half. Objective: To use data from FIT to conduct a cost-effectiveness analysis of alendronate. Design: A...

The most well established antithrombotic treatment for acute coronary syndromes (ACS) is unfractionated heparin (UFH) plus aspirin, but such treatment may not prevent arterial thrombotic events. Low molecular weight heparins (LMWHs) and platelet glycoprotein (GP) IIb/IIIa inhibitors offer...